title: The effect of two different domperidone doses on maternal milk production.
abstract: BACKGROUND
  The benefits of breast milk to the newborn infant are well established. The Canadian Paediatric Society recommends exclusive breastfeeding for the first 6 months of life for healthy, term infants. Mothers of premature newborns, however, may have difficulty providing an adequate supply of breast milk. Domperidone is officially used as a prokinetic agent. However, it is used widely around the world as a galactogogue. Despite its widespread use as a galactogogue, only a small number of investigators have studied domperidone for this indication.
  
  
  OBJECTIVE
  The purpose of this study was to determine an optimal dosage of domperidone as a galactogogue.
  
  
  METHODS
  Eligible subjects were randomized to receive domperidone 10 mg 3 times daily or domperidone 20 mg 3 times daily for 4 weeks. At week 5, the frequency was decreased to twice daily in both groups, and finally once daily for week 6.
  
  
  RESULTS
  Over the entire first 4-week period, there was a significant increase in daily milk volumes within each group (P < .01). The between-group difference over this period, although not statistically significant, was clinically significant. Additionally, there was no significant within- or between-group difference during weeks 5 and 6.
  
  
  CONCLUSIONS
  A dose of domperidone of 20 mg, 3 times daily instead of 10 mg, 3 times daily was associated with a clinical, but not statistically significant, increase in milk production.
authors.affiliation: Pharmacy Services, London Health Sciences Centre, London, Ontario, Canada. dave.knoppert@lhsc.on.ca
authors.forename: David C
authors.initials: DC
authors.lastname: Knoppert
authors.forename: Andrea
authors.initials: A
authors.lastname: Page
authors.forename: Joanne
authors.initials: J
authors.lastname: Warren
authors.forename: Jamie A
authors.initials: JA
authors.lastname: Seabrook
authors.forename: Michelle
authors.initials: M
authors.lastname: Carr
authors.forename: Michelle
authors.initials: M
authors.lastname: Angelini
authors.forename: Diane
authors.initials: D
authors.lastname: Killick
authors.forename: Orlando P
authors.initials: OP
authors.lastname: Dasilva
mesh_terms: D000293:Adolescent; D000328:Adult; D004294:Domperidone / Q000008:administration & dosage* / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D056669:Galactogogues / Q000008:administration & dosage* / Q000627:therapeutic use; D005865:Gestational Age; D006784:Hospitals, Teaching; D006801:Humans; D008875:Middle Aged; D008895:Milk, Human; D047928:Premature Birth; D055815:Young Adult
chemical_list: D018492:Dopamine Antagonists; D056669:Galactogogues; D004294:Domperidone